Triple combination therapy lowered HbA1c more than dual therapy in type 2 diabetes
Key takeaway:
In Indian adults with type 2 diabetes not controlled on metformin alone, the fixed-dose triple combination of glimepiride, voglibose, and extended-release metformin lowered HbA1c more than either dual combination over 24 weeks, with few mild side effects.
Study at a glance
What was studied
Whether a fixed-dose triple oral therapy improves glycemic control more than dual therapy
Study type
Randomized Controlled Trials (RCTs)
duration
Medium-Term (3–12 mo)
Intervention
Glimepiride + voglibose + metformin, Voglibose + metformin, Metformin + glimepiride
Outcomes
HbA1c, Fasting Plasma Glucose, Postprandial glucose, Hypoglycemia events, Adverse events incidence
Funding
Industry sponsored
Main effects
HbA1c ↓ by 1.57% at 24 weeks with triple therapy
More patients reached HbA1c <7% with triple therapy
Fasting glucose ↓ in all treatment groups
Postprandial glucose ↓ in all treatment groups
Hypoglycemia ↔ rare and no severe events were reported
Evidence Summary
| Intervention | Outcome | Measured Change | Study Effect |
|---|---|---|---|
 Glimepiride + voglibose + metformin (Medications) |  Adverse events incidence (Safety) | Uncertain | Limited |
Glimepiride + voglibose + metformin (Medications) |  Fasting Plasma Glucose (Glycemic Control) | Decrease | Limited |
Glimepiride + voglibose + metformin (Medications) | HbA1c (Glycemic Control) | Decrease | Strong |
Glimepiride + voglibose + metformin (Medications) | Hypoglycemia events (Safety) | Uncertain | Limited |
Glimepiride + voglibose + metformin (Medications) | Postprandial glucose (Glycemic Control) | Decrease | Limited |
Metformin + glimepiride (Medications) | Adverse events incidence (Safety) | Uncertain | Limited |
Metformin + glimepiride (Medications) | Fasting Plasma Glucose (Glycemic Control) | Decrease | Limited |
Metformin + glimepiride (Medications) | HbA1c (Glycemic Control) | Decrease | Limited |
Metformin + glimepiride (Medications) | Hypoglycemia events (Safety) | Uncertain | Limited |
Metformin + glimepiride (Medications) | Postprandial glucose (Glycemic Control) | Decrease | Limited |
Voglibose + metformin (Medications) | Adverse events incidence (Safety) | Uncertain | Limited |
Voglibose + metformin (Medications) | Fasting Plasma Glucose (Glycemic Control) | Decrease | Limited |
Voglibose + metformin (Medications) | HbA1c (Glycemic Control) | Decrease | Limited |
Voglibose + metformin (Medications) | Hypoglycemia events (Safety) | Uncertain | Limited |
Voglibose + metformin (Medications) | Postprandial glucose (Glycemic Control) | Decrease | Limited |
Unlock Full Evidence Analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- HbA1c fell more with glimepiride plus voglibose plus extended-release metformin than with either dual-drug comparator at both 12 and 24 weeks.
- By 24 weeks, 62.3% of patients on triple therapy reached HbA1c below 7%, compared with 30.0% and 35.7% in the dual-therapy groups.
- Only two level 1 hypoglycemia events were reported overall, and no serious or severe adverse events occurred.
Who this applies to
These findings apply most directly to adults aged 18 to 65 years with type 2 diabetes in India who remain above target despite stable metformin monotherapy, and who do not have major renal, hepatic, or gastrointestinal exclusion conditions. The results are most relevant to patients with HbA1c between 7.5% and 9.0%.
Keep in Mind
All three treatments improved glucose control, so the main question is the size of the extra benefit from the triple combination. The primary endpoint was an objective lab measure, which strengthens confidence, but the open-label design and industry funding still matter. The study also used fixed-dose combinations and dose uptitration rules that may not fully match every real-world setting.
Between the Lines
- The study was open-label, so participants and clinicians knew which treatment was given.
- The trial included only adults in India with baseline HbA1c up to 9%, so results may not apply to all people with type 2 diabetes.
- Follow-up lasted 24 weeks, so longer-term durability and safety are still uncertain.
- The study was funded by the manufacturer, which increases the need for independent confirmation.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Journal Reference
Mohan B, Kumar SV, Kurmi PH, et al. Efficacy and Safety of Glimepiride, Voglibose, and Metformin ER in Type 2 Diabetes: A Randomized, Active-Controlled Study. J Diabetes. 2026;18(4):e70217. doi:10.1111/1753-0407.70217
Sources
Ranked by clinical relevance and evidence quality.
Key References
Most relevant evidence and guidance related to this research.
Supporting Evidence
Supporting evidence and related resources.
Type 2 diabetes in adults: management
A Guide for People with Type 2 Diabetes | American Diabetes Association
Diabetes Diagnosis & Tests | ADA
Diabetes in America: Prevalence, Statistics, and Economic Impact
Type 2 diabetes - Diagnosis and treatment
Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
13 total sources in this category
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.